NuCana plc to Present at the Jefferies 2017 London Healthcare Conference
(Thomson Reuters ONE) -
EDINBURGH, United Kingdom, Nov. 02, 2017 (GLOBE NEWSWIRE) -- NuCana plc
(Nasdaq:NCNA), a clinical-stage biopharmaceutical company focused on
significantly improving treatment outcomes for cancer patients by applying its
ProTide(TM) technology to transform some of the most widely prescribed
chemotherapy agents into more effective and safer medicines, announced today
that Hugh S. Griffith, Chief Executive Officer of NuCana, will present and host
one-on-one meetings at the Jefferies 2017 London Healthcare Conference in
London, UK.
Event: Jefferies 2017 London Healthcare Conference
Date: Wednesday, November 15, 2017
Time: 11:20 AM GMT
The presentation will be webcast live and available for replay under "Events &
Presentations" in the Investors section of the Company's website at
www.nucana.com.
About NuCana plc
NuCana® is a clinical-stage biopharmaceutical company focused on significantly
improving treatment outcomes for cancer patients by applying our
ProTideTM technology to transform some of the most widely prescribed
chemotherapy agents, nucleoside analogs, into more effective and safer
medicines. While these conventional agents remain part of the standard of care
for the treatment of many solid tumours, their efficacy is limited by cancer
cell resistance mechanisms and they are often poorly tolerated. Utilising our
proprietary technology, we are developing new medicines, ProTides, designed to
overcome key cancer resistance mechanisms and generate much higher
concentrations of anti-cancer metabolites in cancer cells.
Our most advanced ProTide candidates, Acelarin® and NUC-3373, are new chemical
entities derived from the nucleoside analogs gemcitabine and 5-fluorouracil,
respectively, two widely used chemotherapy agents. Acelarin is currently being
evaluated in three clinical studies across several solid tumour indications,
including ovarian cancer, biliary cancer and pancreatic cancer. NUC-3373 is
currently in a Phase 1 study for the potential treatment of a wide range of
advanced solid tumour cancers. For more information, please
visit: www.nucana.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995, including, without
limitation, statements regarding our plans to develop and commercialize our
product candidates, our clinical trials for Acelarin and NUC-3373, and the
potential clinical utility of our product candidates. Words such as "may,"
"will," "could," "would," "should," "anticipate," "predict," "potential,"
"continue," "expects," "intends," "plans," "projects," "believes," "estimates,"
and similar expressions are used to identify forward-looking statements. All
such forward-looking statements are not historical facts but rather are based on
NuCana's current expectations and assumptions and are subject to certain
factors, risks and uncertainties that may cause actual results, outcome of
events, timing and performance to differ materially from those expressed or
implied by such statements. These risks and uncertainties include, but are not
limited to, the risks and uncertainties set forth in the "Risk Factors" section
of our prospectus filed pursuant to Rule 424(b)(4) under the U.S. Securities Act
of 1933, as amended, on September 29, 2017, and subsequent reports that we file
with the U.S. Securities and Exchange Commission. We may not actually achieve
the plans, intentions or expectations disclosed in our forward-looking
statements, and you should not place undue reliance on our forward-looking
statements. All statements contained in this press release are made only as of
the date of this press release, and we do not intend to update this information
except to the extent required by applicable law.
For more information, please contact:
Hugh S. Griffith
Chief Executive Officer
NuCana plc
Tel: +44 131 357 1111
info(at)nucana.com
Westwicke Partners
Chris Brinzey
Tel: +1 339-970-2843
Chris.brinzey(at)westwicke.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: NuCana plc via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 02.11.2017 - 13:00 Uhr
Sprache: Deutsch
News-ID 566444
Anzahl Zeichen: 5145
contact information:
Town:
Edinburgh
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 431 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"NuCana plc to Present at the Jefferies 2017 London Healthcare Conference"
steht unter der journalistisch-redaktionellen Verantwortung von
NuCana plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
